Effects of Dacarbazine and Fotemustine on DNA Repair Enzyme in Blood Cells
Author Information
Author(s): S.M. Lee, N. Thatcher, M. Dougal, G.P. Margison
Primary Institution: Paterson Institute for Cancer Research, Christie Hospital NHS Trust
Hypothesis
The study investigates whether the depletion of the enzyme O6-alkylguanine-DNA alkyltransferase (ATase) in blood cells is related to the dosage of dacarbazine (DTIC) and the number of treatment cycles.
Conclusion
Higher doses of dacarbazine lead to greater depletion of ATase activity in blood cells, which may affect treatment outcomes.
Supporting Evidence
- The mean nadir ATase was 56.3%, 26.4%, and 23.9% for doses of 400, 500, and 800 mg/m2 respectively.
- ATase depletion was less extensive in the first treatment cycle compared to subsequent cycles.
- No ATase depletion was observed in patients receiving fotemustine alone.
Takeaway
This study looked at how different doses of a cancer drug affect a specific enzyme in blood cells that helps repair DNA damage. They found that higher doses make the enzyme work less.
Methodology
Patients received fixed doses of DTIC followed by fotemustine, and ATase levels were measured at various time points after treatment.
Potential Biases
Potential bias due to the non-randomized selection of treatment cycles for ATase measurement.
Limitations
The study's design may have confounded dose and cycle effects due to the random selection of samples.
Participant Demographics
Patients with metastatic melanoma, with varying treatment cycles and dosages.
Statistical Information
P-Value
0.025
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website